PDGF Receptor and its Antagonists: Role in Treatment of PAH

Conference paper
Part of the Advances in Experimental Medicine and Biology book series (volume 661)


Pulmonary Hypertension is a severe lung disease, which is characterized by vasoconstriction and remodelling of the vessel wall. Mostly addressing the increased vascular tone, prostacyclin and its analogues, endothelin-receptor antagonists and phosphodiesterase type 5 inhibitors have been approved for treatment of PAH and represent the current therapeutic options. Mechanistically, these vasodilators decrease pulmonary vascular resistance and reduce thereby shear stress, which is a strong proliferative stimulus per se. Beside the development of new vasodilators, current research focuses on the development of causal treatment regimens aiming a normalization of the vessel structure. Mechanistically, increased proliferation, migration and a resistance to apoptosis of vascular cells represent key events in disease progression. In this context, tyrosine kinase inhibitors like imatinib have been shown to possess reverse remodelling potential in preclinical models of pulmonary hypertension by inducing apoptosis and blocking proliferation. This book chapter describes the role of the platelet derived growth factor (PDGF) receptor and its antagonists for treatment of pulmonary hypertension.


Pulmonary hypertension tyrosine kinase PDGF proliferation growth factor 


  1. 1.
    Yarden Y, Ullrich A (1988) Growth factor receptor tyrosine kinases. Annu Rev Biochem 57:443-478PubMedCrossRefGoogle Scholar
  2. 2.
    Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212PubMedCrossRefGoogle Scholar
  3. 3.
    Ross R, Glomset J, Kariya B, Harker L (1974) A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 71:1207-1210PubMedCrossRefGoogle Scholar
  4. 4.
    Antoniades HN, Scher CD, Stiles CD (1979) Purification of human platelet-derived growth factor. Proc Natl Acad Sci U S A 76:1809-1813PubMedCrossRefGoogle Scholar
  5. 5.
    Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316PubMedGoogle Scholar
  6. 6.
    Fredriksson L, Li H, Eriksson U (2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15:197-204PubMedCrossRefGoogle Scholar
  7. 7.
    Fredriksson L, Li H, Fieber C, Li X, Eriksson U (2004) Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 23:3793-3802PubMedCrossRefGoogle Scholar
  8. 8.
    Feyzi E, Lustig F, Fager G, Spillmann D, Lindahl U, Salmivirta M (1997) Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain. J Biol Chem 272:5518-5524PubMedCrossRefGoogle Scholar
  9. 9.
    Heidaran MA, Beeler JF, Yu JC et al (1993) Differences in substrate specificities of alpha and beta platelet-derived growth factor (PDGF) receptors. Correlation with their ability to mediate PDGF transforming functions. J Biol Chem 268:9287-9295PubMedGoogle Scholar
  10. 10.
    Claesson-Welsh L (1994) Platelet-derived growth factor receptor signals. J Biol Chem 269:32023-32026PubMedGoogle Scholar
  11. 11.
    Stiles CD (1983) The molecular biology of platelet-derived growth factor. Cell 33:653-655PubMedCrossRefGoogle Scholar
  12. 12.
    Grotendorst GR, Chang T, Seppa HE, Kleinman HK, Martin GR (1982) Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol 113:261-266PubMedCrossRefGoogle Scholar
  13. 13.
    Okura T, Igase M, Kitami Y et al (1998) Platelet-derived growth factor induces apoptosis in vascular smooth muscle cells: roles of the Bcl-2 family. Biochim Biophys Acta 1403:245-253PubMedCrossRefGoogle Scholar
  14. 14.
    Rosenkranz S, Kazlauskas A (1999) Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 16:201-216PubMedCrossRefGoogle Scholar
  15. 15.
    Porfiri E, McCormick F (1996) Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1. J Biol Chem 271:5871-5877PubMedCrossRefGoogle Scholar
  16. 16.
    Graves LM, Bornfeldt KE, Sidhu JS et al (1996) Platelet-derived growth factor stimulates protein kinase A through a mitogen-activated protein kinase-dependent pathway in human arterial smooth muscle cells. J Biol Chem 271:505-511PubMedCrossRefGoogle Scholar
  17. 17.
    Assoian RK (1997) Anchorage-dependent cell cycle progression. J Cell Biol 136:1-4PubMedCrossRefGoogle Scholar
  18. 18.
    Uutela M, Lauren J, Bergsten E et al (2001) Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes. Circulation 103:2242-2247PubMedCrossRefGoogle Scholar
  19. 19.
    Betsholtz C, Lindblom P, Bjarnegard M, Enge M, Gerhardt H, Lindahl P (2004) Role of platelet-derived growth factor in mesangium development and vasculopathies: lessons from platelet-derived growth factor and platelet-derived growth factor receptor mutations in mice. Curr Opin Nephrol Hypertens 13:45-52PubMedCrossRefGoogle Scholar
  20. 20.
    Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW (1992) Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 89:507-511PubMedCrossRefGoogle Scholar
  21. 21.
    Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC (1986) Vasoconstriction: a new activity for platelet-derived growth factor. Science 232:87-90PubMedCrossRefGoogle Scholar
  22. 22.
    Ikeda M, Morita C, Mizuno M, Sada T, Koike H, Kurokawa K (1997) PDGF-BB decreases systolic blood pressure through an increase in macrovascular compliance in rats. Am J Physiol 273:H1719-H1726PubMedGoogle Scholar
  23. 23.
    Vassbotn FS, Havnen OK, Heldin CH, Holmsen H (1994) Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor α-receptor. J Biol Chem 269:13874-13879PubMedGoogle Scholar
  24. 24.
    Bryckaert MC, Rendu F, Tobelem G, Wasteson A (1989) Collagen-induced binding to human platelets of platelet-derived growth factor leading to inhibition of P43 and P20 phosphorylation. J Biol Chem 264:4336-4341PubMedGoogle Scholar
  25. 25.
    Tzeng DY, Deuel TF, Huang JS, Baehner RL (1985) Platelet-derived growth factor promotes human peripheral monocyte activation. Blood 66:179-183PubMedGoogle Scholar
  26. 26.
    Lindblom P, Gerhardt H, Liebner S et al (2003) Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 17:1835-1840PubMedCrossRefGoogle Scholar
  27. 27.
    Insull W Jr (2009) The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med 122:S3-S14PubMedCrossRefGoogle Scholar
  28. 28.
    Min SK, Kenagy RD, Clowes AW (2008) Induction of vascular atrophy as a novel approach to treating restenosis. A review. J Vasc Surg 47:662-670PubMedCrossRefGoogle Scholar
  29. 29.
    Belperio JA, Ardehali A (2008) Chemokines and transplant vasculopathy. Circ Res 103:454-466PubMedCrossRefGoogle Scholar
  30. 30.
    Raines EW (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15:237-254PubMedCrossRefGoogle Scholar
  31. 31.
    Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D (1988) Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest 82:1134-1143PubMedCrossRefGoogle Scholar
  32. 32.
    Tanizawa S, Ueda M, van der Loos CM, van der Wal AC, Becker AE (1996) Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Heart 75:549-556PubMedCrossRefGoogle Scholar
  33. 33.
    Noiseux N, Boucher CH, Cartier R, Sirois MG (2000) Bolus endovascular PDGFR-β antisense treatment suppressed intimal hyperplasia in a rat carotid injury model. Circulation 102:1330-1336PubMedCrossRefGoogle Scholar
  34. 34.
    Leppänen O, Janjic N, Carlsson MA et al (2000) Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 20:E89-E95PubMedCrossRefGoogle Scholar
  35. 35.
    Yu JC, Lokker NA, Hollenbach S et al (2001) Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther 298:1172-1178PubMedGoogle Scholar
  36. 36.
    Hart CE, Kraiss LW, Vergel S et al (1999) PDGFβ receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 99:564-569PubMedCrossRefGoogle Scholar
  37. 37.
    Rutherford C, Martin W, Carrier M, Anggard EE, Ferns GA (1997) Endogenously elicited antibodies to platelet derived growth factor-BB and platelet cytosolic protein inhibit aortic lesion development in the cholesterol-fed rabbit. Int J Exp Pathol 78:21-32PubMedCrossRefGoogle Scholar
  38. 38.
    Sano H, Sudo T, Yokode M et al (2001) Functional blockade of platelet-derived growth factor receptor-β but not of receptor-α prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 103:2955-2960PubMedCrossRefGoogle Scholar
  39. 39.
    Bilder G, Wentz T, Leadley R et al (1999) Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. Circulation 99:3292-3299CrossRefGoogle Scholar
  40. 40.
    Rubin LJ (2006) Pulmonary arterial hypertension. Proc Am Thorac Soc 3:111-115PubMedCrossRefGoogle Scholar
  41. 41.
    Barst RJ (2005) PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115:2691-2694PubMedCrossRefGoogle Scholar
  42. 42.
    Humbert M, Morrell NW, Archer SL et al (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S-24SPubMedCrossRefGoogle Scholar
  43. 43.
    Jeffery TK, Morrell NW (2002) Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 45:173-202PubMedCrossRefGoogle Scholar
  44. 44.
    Cool CD, Stewart JS, Werahera P et al (1999) Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155:411-419PubMedCrossRefGoogle Scholar
  45. 45.
    Humbert M, Montani D, Perros F, Dorfmüller P, Adnot S, Eddahibi S (2008) Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul Pharmacol 49:113-118PubMedCrossRefGoogle Scholar
  46. 46.
    Olsson KM, Hoeper MM (2009) Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. Drug Discov Today 14:284-290PubMedCrossRefGoogle Scholar
  47. 47.
    Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR (2009) Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 121:69-88PubMedCrossRefGoogle Scholar
  48. 48.
    Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM (1998) Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101:927-934PubMedCrossRefGoogle Scholar
  49. 49.
    Schermuly RT, Dony E, Ghofrani HA et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811-2821PubMedCrossRefGoogle Scholar
  50. 50.
    Humbert M, Monti G, Fartoukh M et al (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11:554-559PubMedGoogle Scholar
  51. 51.
    Yu Y, Sweeney M, Zhang S et al (2003) PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am J Physiol Cell Physiol 284:C316-C330PubMedGoogle Scholar
  52. 52.
    Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH (2003) Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284:L826-L833PubMedGoogle Scholar
  53. 53.
    Jankov RP, Kantores C, Belcastro R et al (2005) A role for platelet-derived growth factor beta-receptor in a newborn rat model of endothelin-mediated pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 288:L1162-L1170PubMedCrossRefGoogle Scholar
  54. 54.
    Perros F, Montani D, Dorfmuller P et al (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178:81-88PubMedCrossRefGoogle Scholar
  55. 55.
    Ghofrani HA, Seeger W, Grimminger F (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353:1412-1413PubMedCrossRefGoogle Scholar
  56. 56.
    Patterson KC, Weissmann A, Ahmadi T, Farber HW (2006) Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 145:152-153PubMedGoogle Scholar
  57. 57.
    Souza R, Sitbon O, Parent F, Simonneau G, Humbert M (2006) Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61:736PubMedCrossRefGoogle Scholar
  58. 58.
    Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344PubMedCrossRefGoogle Scholar
  59. 59.
    Kerkelä R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916PubMedCrossRefGoogle Scholar
  60. 60.
    Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880PubMedCrossRefGoogle Scholar
  61. 61.
    Will Y, Dykens JA, Nadanaciva S et al (2008) Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci 106:153-161PubMedCrossRefGoogle Scholar
  62. 62.
    Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.University Hospital, Medical Clinic II/VGiessenGermany
  2. 2.Department of Lung Development and RemodelingMax-Planck-Institute for Heart and Lung ResearchBad NauheimGermany

Personalised recommendations